| BackgroundParkinson’s disease (PD) is one of movement disorders. The person suffered PDshould require long-time, systematic and standardized treatment when they’rediagnosed clearly. The most effective drug to the PD’s sufferers is dopamine (DA)replacement therapy among the therapeutic plan. However, its long-term use can leadto the problems such as wearing-off, the intractable dyskinesia and so on. Some newtreatment for PD has been gradually in clinical application due to its certainadvantages in comparison with the traditional dopamine replacement drugs in recentyears. Selegiline is widely used in clinical medical treatment activity as selectivemonoamine oxidase type B inhibitors (MAO-BI) because of its certain advantage thatit can obviously alleviate the motor symptoms of PD and slow down the occurrence ofmotor complications. There are a certain number of clinical trials abroad and primarysystematic evaluation on selegiline with PD to prove its clinical curative effect, but nosystematic evaluation about the therapeutic effect of selegiline with Chinese patients.It is in recent years that the clinical trials about selegiline for Chinese PD’s patientsare gradually increasing. As a consequence, an updated systematic evaluation on theapplication of selegiline for PD is urgently needed to provide more detailed andreliable evidence of evidence-based medicine (EBM).ObjectiveThis study will analyze the Curative effect of selegiline for PD patients withdifferent races in the subgroup under the circumstances of different interventionstrategies through the Meta analysis method to provide effective evidence-based basisfor its clinical application.MethodsWe search out all clinical trials about the application of selegiline for PDpublished from January1982to February2015. In combination with the formulationand exclusion criteria, we select the final related literature and pick out the available data after reading the full text. At last, we use Revman5.3software to evaluate theeffect rate of selegiline in different interventions and racially diverse by computingrelative risk (RR), mean differences (MD), standard deviation (SD) and95%confidence intervals (95%CI), rowing Z test.ResultsThe result shows that we found25references involving4263patients wereincluded reported the therapeutic effect of selegiline for PD. The comprehensiveanalysis showed compared with placebo the total effective rate with RR=1.22,95%CI(1.15,1.30) and P﹤0.00001. The effective cases which used selegiline alone is withRR=0.99,95%CI (0.89,1.11) and P=0.91while the result in the group which appliedselegiline on the basis of other therapeutic schemes is with RR=1.13,95%CI(1.04,1.23) and P=0.004.This study analyzed UPDRS scores in Caucasian with SMD=-0.68,95%CI (-0.80,-0.53) and P＜0.00001while the effective cases in Mongoloidwith RR=1.33,95%CI (1.19,1.48) and P＜0.00001. The analysis show the adversereaction in the application of selegiline for PD with RR=0.61,95%CI (0.34,1.11)and P=0.10.ConclusionApplication of selegiline based on other therapies in clinical trials can benefit themajority of patients. What’s more, it is equally effective for Mongolia and Caucasian.But the curative effect in the process of applying selegiline separately for PD was notexact. The drug itself doesn’t lead to the adverse reactions during the course oftreatment. Available evidence suggests that selegiline compared with control grouphave higher efficiency in its Clinical application, and these results can be regarded asgrade Ⅲaevidence-based reference evidence... |
PDF Full Text Request